The treatment of breast cancer requires a multidisciplinary approach incorporating surgery, radiotherapy, hormonal agents, targeted therapies, and chemotherapy. Treatment decisions are influenced by disease stage, resectability, and HER2 and HR status. Targeted treatment options for the HR-positive, HER2-negative segment have expanded in the United States following the market entries of Pfizer’s Ibrance (2015) and Novartis’s Kisqali (2017). This study shines a spotlight on the current treatment dynamics for HR-positive, HER2-negative breast cancer and examines how the triple-negative breast cancer population is now managed.
Questions answered:

  • What are the key drivers and obstacles determining current prescribing patterns for Ibrance in HR-positive/HER2-negative metastatic breast cancer?
  • What is the uptake of recently approved Kisqali in newly diagnosed HR-positive/HER2-negative metastatic breast cancer? What is surveyed oncologists’ perception of Kisqali versus Ibrance?
  • In the absence of any approved targeted therapy for triple-negative breast cancer, what is the patient share of key chemotherapeutic agents and regimens prescribed to newly diagnosed patients?
  • What is the most-frequently prescribed sequence of treatment for HR-positive/HER2-negative metastatic breast cancer?

Key drugs covered:

  • Kisqali
  • Ibrance
  • Afinitor
  • Abraxane
  • Faslodex

Companies mentioned:

  • Pfizer
  • Novartis

Related Reports

Breast Cancer - Landscape & Forecast - Disease Landscape & Forecast

The breast cancer market is rapidly evolving and presents new commercial opportunities for drug developers. CDK4/6 inhibitors (Pfizer’s Ibrance,...

View Details

Breast Cancer - Geographic Focus: China - Breast Cancer - China In-Depth (China)

Breast cancer is the most commonly diagnosed cancer among Chinese women. A high incidence and a prolonged treatment duration make the treatment of breast cancer a lucrative commercial opportunity f...

View Details

Non-Hodgkin's Lymphoma And Chronic Lymphocytic Leukemia - Epidemiology - Janssen Proprietary Content

In this report, comissioned by Janssen in October, 2020, we estimate the following mantle cell lymphoma (MCL) patient populations for the years 2020-2030: Diagn...

View Details

Breast Cancer - Current Treatment - Detailed, Expanded Analysis (US)

Hormone receptor (HR)-positive / HER2-negative breast cancer is the most prevalent breast cancer subtype. Treatment decisions are influenced by disease stage, genetic test score, menopausal status,...

View Details